- p15^INK4b, encoded by the CDKN2B gene, is a member of the INK4 family of cyclin‑dependent kinase inhibitors, which also includes p16^INK4a, p18^INK4c, and p19^INK4d. Like other INK4 proteins, p15 specifically binds to CDK4 and CDK6, preventing their association with cyclin D. This inhibition blocks phosphorylation of the retinoblastoma protein (Rb), enforcing a G₁‑phase arrest and preventing premature entry into S phase. Through this mechanism, p15 acts as a critical regulator of cell‑cycle restraint, ensuring that proliferation is tightly controlled and responsive to extracellular cues.
- p15^INK4b is strongly induced by transforming growth factor‑β (TGF‑β) signalling, making it a key mediator of growth inhibition in response to anti‑proliferative signals. When TGF‑β engages its receptors, downstream SMAD transcription factors activate CDKN2B expression, leading to accumulation of p15 and suppression of CDK4/6 activity. This pathway is essential for maintaining tissue homeostasis, preventing excessive proliferation, and coordinating cell‑cycle arrest with differentiation. In contrast to p16^INK4a, which is closely associated with senescence and stress responses, p15 primarily functions as a physiological inhibitor of mitogenic signalling.
- Regulation of p15 occurs at multiple levels. Transcriptionally, p15 is activated by TGF‑β, BMP, and other growth‑inhibitory pathways. Epigenetic mechanisms also play a major role: promoter methylation of CDKN2B is frequently observed in cancers, leading to loss of p15 expression and removal of a critical brake on proliferation. Post‑translationally, p15 is relatively stable compared with Cip/Kip inhibitors such as p27^Kip1, and its abundance is primarily determined by transcriptional control rather than rapid proteasomal degradation. This stability ensures that once p15 is induced, its inhibitory effects persist long enough to enforce cell‑cycle arrest.
- Beyond its canonical role in CDK4/6 inhibition, p15 contributes to broader biological processes. It plays a role in haematopoietic stem‑cell regulation, helping maintain quiescence and preventing uncontrolled expansion of progenitor populations. In epithelial tissues, p15 participates in differentiation programmes by stabilising cell‑cycle exit. In the immune system, p15 influences lymphocyte development and activation thresholds. These diverse functions highlight p15’s importance in coordinating proliferation with specialised physiological demands.
- Dysregulation of p15 has significant implications for human disease. Loss of CDKN2B expression is common in leukaemia, lymphoma, glioma, colorectal cancer, and other malignancies. Reduced p15 levels remove a key inhibitory checkpoint, allowing excessive CDK4/6 activity, uncontrolled Rb phosphorylation, and inappropriate entry into S phase. Epigenetic silencing of p15 is particularly frequent in tumours with defective TGF‑β signalling, reflecting the close relationship between p15 and anti‑proliferative pathways. Conversely, overexpression of p15 can impair tissue regeneration or contribute to pathological growth arrest. Because p15 lies upstream of the Rb pathway, its status influences tumour behaviour and response to CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib.
- In summary, p15^INK4b is a crucial regulator of G₁‑phase progression, growth inhibition, and tissue homeostasis. Its selective inhibition of CDK4/6, strong induction by TGF‑β, and involvement in differentiation and stem‑cell regulation distinguish it from other INK4 family members. Understanding p15 biology provides insight into cell‑cycle control, tumour suppression, and therapeutic strategies targeting the Rb pathway.
